Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.61 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | MPO | P05164 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11107537 | 0.85 | KDM4E (0.80) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| SCHEMBL7273110 | 0.83 | CYP1A2 (0.63) | KDM4EMAPTCYP1A2CYP2C19CYP2C9 | |
| SCHEMBL14990877 | 0.82 | CYP1A2 (0.57) | KDM4ECYP1A2CYP2C19CYP2C9MPO | |
| SCHEMBL3246848 | 0.82 | CYP1A2 (0.62) | KDM4EMAPTCYP1A2CYP2C19CYP2C9 | |
| SCHEMBL10988622 | 0.82 | ALDH1A1 (0.68) | HIF1ACYP1A2CYP2C19CYP2C9CYP3A4 | |
| Hippuric Acid SCHEMBL7486 | 0.81 | GAA (0.68) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| SCHEMBL22030672 | 0.81 | GAA (0.68) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| Hippuric Acid SCHEMBL428479 | 0.81 | GAA (0.68) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| SCHEMBL9339173 | 0.81 | MAPT (0.69) | KDM4EMAPTCYP1A2CYP2C19CYP2C9 | |
| SCHEMBL2998085 | 0.81 | ALDH1A1 (0.64) | KDM4ECYP1A2CYP2C19CYP2C9MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4051269-A1 | D-AMPHETAMINE COMPOUNDS, COMPOSITIONS, AND PROCESSES FOR MAKING AND USING THE SAME | KemPharm, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-107827815-B | Fluoroquinolone amino derivatives and application thereof in preventing and treating citrus diseases | 西南大学 | 2021-08-03 | — | — | CN | disclosed |
| WO-2021086426-A1 | D-AMPHETAMINE COMPOUNDS, COMPOSITIONS, AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-10857211-B2 | Genomic instability markers in Fanconi anemia | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190391092-A1 | METABOLIC PROFILING WITH MAGNETIC RESONANCE MASS SPECTROMETRY (MRMS) | Oregon Institute of Science and Medicine | 2019-12-26 | — | — | US | disclosed |
| CN-107827815-A | Fluoroquinolones aminoderivative and its purposes for preventing and treating citrus disease | 西南大学 | 2018-03-23 | — | — | CN | disclosed |
| US-20170100462-A1 | GENOMIC INSTABILITY MARKERS IN FANCONI ANEMIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-13 | — | — | US | disclosed |
| WO-2015179779-A1 | GENOMIC INSTABILITY MARKERS IN FANCONI ANEMIA | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2015-11-26 | — | — | WO | disclosed |
| US-8980908-B2 | Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980908-B2 | Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2802687-A1 | IMPROVEMENTS IN COATING TECHNOLOGY | Johnson Matthey Public Limited Company (GB) | 2014-11-19 | — | — | EP | disclosed |
| US-8772308-B2 | Non-peptidyl, potent, and selective mu opioid receptor antagonists | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772308-B2 | Non-peptidyl, potent, and selective mu opioid receptor antagonists | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2663670-A2 | IMPROVEMENTS IN COATING TECHNOLOGY | Johnson Matthey Public Limited Company (GB) | 2013-11-20 | — | — | EP | disclosed |
| WO-2013104877-A1 | IMPROVEMENTS IN COATING TECHNOLOGY | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2013-07-18 | — | — | WO | disclosed |
| WO-2012095667-A2 | IMPROVEMENTS IN COATING TECHNOLOGY | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2012-07-19 | — | — | WO | disclosed |
| US-20110306628-A1 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS | VIRGINIA COMMONWEALTH UNIVERSITY | 2011-12-15 | — | — | US | disclosed |
| US-20110306628-A1 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS | VIRGINIA COMMONWEALTH UNIVERSITY | 2011-12-15 | — | — | US | disclosed |
| WO-2010083384-A2 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2010-07-22 | — | — | WO | disclosed |
| US-5756650-A | COMPOSITION COMPRISING POLYAMIC ACID, CURE ACCELERATOR SELECTED FROM GROUP CONSISTING OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AMINO ACID COMPOUND, AROMATIC COMPOUND HAVING TWO OR MORE HYDROXYL GROUPS | KABUSHIKI KAISHA TOSHIBA (JP) | 1998-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306628-A1 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRK1, OPRD1 | KDM4E 3891/4885MAPT 1886/4885HIF1A 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.